CME Information
2026 Thomas C. Shea Clinical Cancer Symposium
Accreditation Statement
The School of Medicine of the University of North Carolina at Chapel Hill is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Statement
The School of Medicine of the University of North Carolina at Chapel Hill designates this live activity for a maximum of 5.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure statement
This activity has been planned and implemented under the sole supervision of the Course Directors Matt Milowsky, MD, William Kim, MD, and Kaitlin Morrison, PhD, in association with the UNC Office of Continuing Professional Development (CPD). Dr. Morrison and CPD staff have no relevant financial relationships with ineligible companies as defined by the ACCME.
Dr. Kim held stock in Abbvie, Amgen, Apellis, Arvinas, BeiGene, Bristol-Myers Squibb, Eli Lilly, Moderna, Natera, Novo Nordisk, Revolution Med, Tango, and Viking; and received research support from Merck. These relationships have been mitigated; Dr. Kim has recused himself from planning content related to products or services offered by these companies.
Dr. Milowsky held stock in Gilead Sciences and Pfizer; provided uncompensated consulting work for G1 Therapeutics and Loxo/Lilly; and received research support from Acrivon Therapeutics, ALX Oncology, Amgen, Astellas Pharma, Bristol-Myers Squibb, Flare Therapeutics, G1 Therapeutics, Loxo/Lilly, Merck, Novartis, OncoC4, Pfizer, and Roche. These relationships have been mitigated; Dr. Milowsky has recused himself from planning content related to products or services offered by these companies.
Presenters
Dr. Dorff received speaker fees from Johnson & Johnson (ended 11/25); consulting fees from Astellas, AstraZeneca, Bayer, Janssen, Novartis, and Pfizer; and reseach support from Abbvie, Amgen, AstraZeneca, and Dendreon.
Dr. Galsky received speaker fees from ER Squibb & Sons (ended 12/24) and Pfizer (ended 9/25).
Dr. Grivas received consulting fees from AbbVie, Astellas Pharma, AstraZeneca, Bicycle Therapeutics, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, EMD Serono, Foundation Medicine, Gilead Sciences, Janssen, MSD, Natera, Pfizer, Replimune, Roche, Strata Oncology, Tyra Biosciences, and Urogen; and research support from Acrivon Therapeutics, ALX Oncology, Bristol-Myers Squibb, EMD Serono, Genentech, Gilead Sciences, and MSD.
Dr. Kim had the financial relationships listed above.
Dr. Milowsky had the financial relationships listed above.
Dr. Morgans received consulting fees from Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Curium, Johnson & Johnson, Lantheus, Merck, Novartis, Pfizer, Teliix, and Tolmar; and research support from Bayer and Pfizer.
Dr Sridhar received consulting fees from AstraZeneca, Bayer, Bicycle Therapeutics, BMS, Daiichi Sankyo, EMD Serono, Gilead, Ipssen, Merck, Pfizer; and research support from Bayer, EMD Serono, and Pfizer.
Dr. Tagawa held stock options in Convergent and stock in Alkido; received speaker fees from PER and PRIME; received consulting fees from Abbvie, Abdera, Aikido Pharma, Ambrx, Amgen, Astellas, Bayer, Biohaven, Blue Earth, Boston Scientific, Clarity, Clovis, Convergent Therapeutics, Daiichi Sankyo, Eisai, EMD Serono, Endocyte, General Electric, Genentech, Genomic Health, Gilead, Immunomedics, Johnson & Johnson, Karyopharm, Lantheus, Lilly, Merck, Myovant, Novartis, Pfizer, POINT Biopharma, Regeneron, Sanofi, Seattle Genetics, Telix Pharma, Tolmar, and TransThera; received research support from Sanofi, Abbvie, AIQ, Ambrx, Amgen, Astellas, AstraZeneca, Atlab, Aveo, Bayer, Boehringer Ingelheim, BMS, Clarity, Clovis, Endocyte, Genentech, Gilead, Immunomedics, Inovio, Janux, Johnson & Johnson, Karyopharm, Lilly, Merck, Millennium, Novartis, POINT Biopharma, Rexahn, Seattle Genetics, Telix; and holds patents with Gilead and Immunomedics.
Dr. Westerman received speaker fees from CG Oncology.
Dr. Fahey, Dr. Morrison, and Dr. Wobker have no relevant financial relationships with ineligible companies as defined by the ACCME.